huahaipharm(SH:600521)2017-04-24 16:00Financial Performance - Operating revenue for the period reached CNY 1,129,537,585.37, representing a 16.69% increase year-on-year[5] - Net profit attributable to shareholders was CNY 140,069,587.43, up 15.01% from the same period last year[5] - Basic earnings per share increased by 16.67% to CNY 0.14[5] - Total revenue for Q1 2017 reached ¥1,129,537,585.37, an increase of 16.67% compared to ¥968,008,230.26 in Q1 2016[20] - Operating profit for Q1 2017 was ¥107,763,799.93, down 21.92% from ¥137,930,108.67 in the same period last year[21] - Net profit attributable to shareholders for Q1 2017 was ¥140,069,587.43, a 15.76% increase from ¥121,791,096.58 in Q1 2016[21] - Operating profit increased to ¥153,576,823.63, representing a growth of 14.6% from ¥134,085,531.36 in the previous period[26] - The total profit for the current period was ¥184,586,458.48, an increase of 39.3% from ¥132,532,570.86 in the previous period[26] Assets and Liabilities - Total assets increased by 5.04% to CNY 7,065,626,278.36 compared to the end of the previous year[5] - Total assets as of the end of Q1 2017 amounted to ¥6,273,588,832.39, up from ¥5,954,414,007.60 at the end of Q1 2016[19] - Total liabilities rose from 2,148,552,262.98 RMB at the beginning of the year to 2,353,847,828.24 RMB, an increase of about 9.5%[15] - Total liabilities increased to ¥1,816,014,562.16 in Q1 2017, compared to ¥1,662,937,157.12 in Q1 2016, reflecting a growth of 9.19%[19] - Current liabilities totaled ¥1,228,091,922.38, an increase of 14.36% from ¥1,074,194,462.09 in the previous year[19] - The company's total equity increased from 4,577,831,762.22 RMB to 4,711,778,450.12 RMB, reflecting a growth of approximately 2.9%[15] Cash Flow - The net cash flow from operating activities was negative CNY 132,037,785.19, a significant decline of 2,526.29% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of ¥132,037,785.19, worsening from a net outflow of ¥5,027,531.64 in the previous period[28] - Total cash inflow from operating activities was 647,397,155.71 RMB, compared to 603,091,161.28 RMB in Q1 2016, reflecting a growth of approximately 7.3%[31] - Cash outflow from operating activities totaled 734,752,075.89 RMB, up from 511,990,382.54 RMB, indicating a significant increase of about 43.6%[31] - Cash inflow from financing activities was 310,000,000.00 RMB, down from 412,000,000.00 RMB in the previous year, representing a decline of approximately 24.8%[32] - Net cash flow from financing activities was 249,209,133.66 RMB, compared to 286,302,436.69 RMB in Q1 2016, a decrease of about 12.9%[32] Expenses - Sales expenses surged by 108% to CNY 213,047,698.62 as the company intensified market promotion efforts[8] - The company incurred sales expenses of ¥68,742,584.46, which is a significant increase from ¥37,326,104.63 in the previous period[26] - The company reported a significant increase in tax expenses, totaling ¥26,220,117.99, compared to ¥20,894,758.19 in the previous period[26] Government Support - The company received government subsidies amounting to CNY 34,223,711.65, which positively impacted other income[5] - The company reported a significant increase in other income, totaling CNY 35,743,458.22, primarily from government subsidies[8] Inventory and Receivables - Accounts receivable increased from 1,280,916,526.45 RMB at the beginning of the year to 1,450,272,911.67 RMB by the end of Q1 2017, indicating a growth of approximately 13.3%[13] - Inventory rose from 1,330,231,893.14 RMB at the beginning of the year to 1,372,266,684.69 RMB, reflecting an increase of about 3.2%[13] - The company’s inventory decreased slightly to ¥1,043,504,661.18 from ¥1,050,852,101.87 year-over-year[18] Share Repurchase - The company repurchased and canceled 489,320 shares of restricted stock that did not meet the unlocking conditions as of January 9, 2017[9]